Which funds bought or sold TMO in Q3 2026?
Thermo Fisher Scientific Inc. 16 funds bought, 16 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was +$5.9B. See also what famous investors say about TMO.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Fidelity+$5.5B
- JPMorgan+$1.3B
- BlackRock+$842M
- Lone PineNEW+$673M
- Holocene+$361M
- Ameriprise+$349M
- MaverickNEW+$201M
- Invesco+$160M
- Arrowstreet+$151M
- Amundi+$142M
- Viking−$687M
- Farallon−$407M
- D1−$318M
- D. E. Shaw−$317M
- QRT−$314M
- Citadel−$287M
- UBS−$277M
- Balyasny−$256M
- Schwab−$192M
- Glenview−$124M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (16)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Fidelity Asset manager | Added+57.4% | +$5.5B | $15.0B |
| JPMorgan Bank & broker | Added+22.7% | +$1.3B | $7.1B |
| BlackRock Index giant | Added+4% | +$842M | $21.7B |
| Lone Pine Hedge fund | New | +$673M | $673M |
| Holocene Hedge fund | Added+1035.7% | +$361M | $396M |
| Ameriprise Asset manager | Added+33.4% | +$349M | $1.4B |
| Maverick Hedge fund | New | +$201M | $201M |
| Invesco Asset manager | Added+10.9% | +$160M | $1.6B |
| Arrowstreet Quant & multi-strategy | Added+22.2% | +$151M | $831M |
| Amundi Asset manager | Added+11.6% | +$142M | $1.4B |
| Susquehanna Quant & multi-strategy | Added+210.9% | +$99M | $145M |
| Bridgewater Hedge fund | Added+1094.4% | +$96M | $104M |
| AllianceBernstein Asset manager | Added+5.6% | +$70M | $1.3B |
| Wells Fargo Bank & broker | Added+6.1% | +$60M | $1.0B |
| Fisher Investments Asset manager | Added+2.6% | +$50M | $2.0B |
| Temasek Sovereign & pension | Added+3.7% | +$29M | $814M |
Sold (16)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Viking Hedge fund | Trimmed-52.5% | −$687M | $621M |
| Farallon Hedge fund | Trimmed-57.5% | −$407M | $301M |
| D1 Growth / crossover | Trimmed-57.7% | −$318M | $234M |
| D. E. Shaw Quant & multi-strategy | Trimmed-73.1% | −$317M | $116M |
| QRT Quant & multi-strategy | Trimmed-94.5% | −$314M | $18M |
| Citadel Quant & multi-strategy | Trimmed-74% | −$287M | $101M |
| UBS Bank & broker | Trimmed-16.3% | −$277M | $1.4B |
| Balyasny Quant & multi-strategy | Trimmed-84.2% | −$256M | $48M |
| Schwab Index giant | Trimmed-9.1% | −$192M | $1.9B |
| Glenview Hedge fund | Trimmed-29.2% | −$124M | $300M |
| Man Group Quant & multi-strategy | Trimmed-63.1% | −$83M | $49M |
| PRIMECAP Growth / crossover | Trimmed-4.4% | −$59M | $1.3B |
| Tudor Hedge fund | Sold out | −$36M | — |
| Jennison Growth / crossover | Trimmed-18.9% | −$34M | $147M |
| Baillie Gifford Growth / crossover | Trimmed-6.3% | −$27M | $409M |
| Duquesne Family office & foundation | Sold out | −$10M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.